Emir CELIK
- Profession: Internal Medicine & Medical Oncology
- Experience: 8 years in Internal Medicine and 4 years in Medical Oncology
Professional Summary
In Cerrahpasa Medical School, one of Turkey's largest and most prestigious medical institutions, I completed my medical education, internal medicine residency, and medical oncology fellowship program without break. The clinic where I completed my medical oncology fellowship is a high-volume facility. Our institution holds weekly multidisciplinary meetings with specialists from all surgical disciplines. I currently work in a state hospital as a medical oncology specialist. In our center, we frequently use current chemotherapy, immunotherapy, and oral targeted therapies.
Education
- 2018-2021 Medical Oncology Fellowship, Cerrahpasa Faculty of Medicine
- 2014-2018 Internal Medicine Residency, Cerrahpasa Faculty of Medicine
- 2007-2013 Cerrahpasa Faculty of Medicine, Istanbul, Turkey
Published Work
- A) Articles published in peer-reviewed international journals
A1. Celik E, Aslan MS, Sengul Samanci N, et al. The Relationship Between Symptom Severity and Caregiver Burden in Cancer Patients Under Palliative Care: A Cross-Sectional Study. J Palliat Care. 2022;37(1):48-54.
A2. Samanci NS, Akdogan S, Celik E, Kutlu O, Ulgen OA, Demirelli FH. Facial cutaneous metastasis of rectal adenocarcinoma. North Clin Istanb. 2020;8(5):518-520.
A3. Celik E, Samanci NS, Karadag M, Demirci NS, Demirelli FH, Ozguroglu M. The relationship between eGFR and capecitabine efficacy/toxicity in metastatic breast cancer. Med Oncol. 2021;38(1):11.
A4. Celik E, Samanci NS, Karadag M, et al. Classical versus non-classical EGFR mutations: Erlotinib response and impact of renal insufficiency. J Oncol Pharm Pract. 2021;27(7):1665-1673.
A5. Sengul Samanci N, Cikman DI, Oruc K, et al. Immune-related adverse events associated with immune checkpoint inhibitors in patients with cancer. Tumori. 2021;107(4):304-310.
A6. Celik E, Dokur M. The most cited articles on cancer immunotherapy: An update study. J BUON. 2020;25(2):1178-1192.
A7. Celik E, Suzan V, Samanci NS, et al. Sarcopenia assessment by new EWGSOP2 criteria for predicting chemotherapy dose-limiting toxicity in patients with gastrointestinal tract tumors. Eur Geriatr Med. 2022;13(1):267-274. A8. Sengul Samanci N, Ozan T, Çelik E, Demirelli FH. Optic Neuritis Related to Atezolizumab Treatment in a Patient With Metastatic Non-Small-Cell Lung Cancer. JCO Oncol Pract. 2020;16(2):96-98.
A9. Değerli E, Derin S, Oruç K, et al. The demographic characteristics, prognosis, and relationship with cancer subtypes of hospitalized COVID-19 patients with malignancy: A single-center experience. J Med Virol. 2021;93(10):5839-5845.
A10. Samanci NS, Celik E. The top 100 cited articles in lung cancer - a bibliometric analysis. Contemp Oncol (Pozn). 2020;24(1):17-28.
A11. Sengul Samanci N, Çelik E, Bagcilar O, et al. Use of volumetric CT scanning to predict tumor staging and survival in pancreatic cancer patients that are to be administered curative resection. J Surg Oncol. 2021;123(8):1757-1763.
A12. Bilgin B, Sendur MAN, Yucel S, et al. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study. J Cancer Res Clin Oncol. 2021;147(7):2145-2152.
A13. Ozkaya HM, Sahin S, Korkmaz OP, et al. Patients with acromegaly might not be at higher risk for dopamine agonist-induced impulse control disorders than those with prolactinomas. Growth Horm IGF Res. 2020;55:101356.
A14. Sengul Samanci N, Celik E, Akovalı B, Sager S, Demirelli FH. Complete response after ceritinib treatment in non-small cell lung cancer in an elderly patient. J Oncol Pharm Pract. 2020;26(8):2031-2033
A15. Sengul Samanci N, Yılmaz U, Bedir S, et al. Follicular lymphoma generating in a patient with non-small cell lung cancer following nivolumab discontinuation. J Oncol Pharm Pract. 2020;26(8):2042-2046.
A16. Sengul Samanci N, Çelik E, Bagcilar O, et al. Loss of skeletal muscle area and fat-free mass during dabrafenib/trametinib and vemurafenib/cobimetinib treatments in patients with BRAF-mutant metastatic malignant melanoma. Melanoma Res. 2020;30(5):477-483.
A17. Celik E, Ozkaya HM, Poyraz BC, Saglam T, Kadioglu P. Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up. Endocrine. 2018;62(3):692-700.
A18. Celik, E., Sengul Samanci, N., Derin, S., Bedir, S., Degerli, E., Oruc, K., ... & Turna, H. (2022). A single center’s experience of the extra-pulmonary neuroendocrine carcinomas. Northern Clinics of İstanbul, 9(1), 35-40.
A19. Samanci, N. S., Guliyev, M., Degerli, E., Celik, E., & Turna, Z. H. (2020). A rare case of cardiac toxicity in a patient with imatinib treatment: Case report.
A20. Çelik, E., Dokur, M., Borku Uysal, B., Şengül Samancı, N., & Demirelli, F. H. (2020). Comparison of attention for cancer research on social media versus academia: An altmetric score analysis.
A21. Gursoy, P., Tatli, A. M., Erdem, D., Goker, E., Celik, E., Demirci, N. S., Sakin, A., Atci, M. M., Bayram, E., Telli, T. A., Bilgin, B., Bilici, A., Akangunduz, B., Balli, S., Demirkazik, A., Selçukbiricik, F., Menekse, S., Cavdar, E., Ozturk, A., Bekmez, E. T., … Yumuk, P. F. (2022). Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study. Journal of cancer research and clinical oncology
- B) Articles published in national peer-reviewed journals
B1. SAMANCI, N. Ş., CELİK, E., DEGERLİ, E., KASAP, M., Kerem, O. R. U. C., BEDİR, S., ... & DEMİRELLİ, F. FACTORS OF AFFECTING SLEEP QUALITY IN CANCER PATIENTS. Namık Kemal Tıp Dergisi, 8(2), 138-144.
B2. Samanci, N. S., Gursu, R. U., Bozkaya, Y., Arslan, E., Ulusan, M. B., Trablus, F. D. C., ... & Mermut10, O. (2021). Response Rates and Predictive Factors of Pathological Complete Response to Neoadjuvant Chemotherapy in Luminal B HER2 Negative Breast Cancer.
B3. Degerli, E., Samanci, N. S. D. N. S., Celik, E., & Taparli, O. E. (2021). Effect of Smokıng Status on Hematologıcal Toxıcıtıes and Effectıveness of Fırst-Lıne Platınum Based Chemotherapy Admınıstered to Patıents wıth Non-Small Cell Lung Cancer. Eurasian Journal of Medical Investigation, 5(2), 189.
B4. Celik, E., Samanci, N. S., Karadag, M., Demirci, N. S., & Demirelli, F. H. (2021). Could Systemic İnflammation-Based Prognostic Scores Predict The Clinical Outcome in Patients with Breast Cancer Treated with Everolimus Plus Exemestane?. Eurasian Journal of Medical Investigation, 5(2), 225.
B5. Suzan, V., Yavuzer, H., Bayramlar, O. F., Emiroglu, T., Arman, P., Bag, R., ... & Erdincler, D. S. Effect of Pneumococcal Vaccination and Other Factors on Prognosis in Patients Following with Pneumonia in Geriatric Clinic.
B6. ÇELİK, E., ASLAN, M. Ş., SAMANCI, N. Ş., KARADAĞ, M., SUZAN, V., ÇELİK, Y. Ç., ... & DEMİRELLİ, F. H. (2021). Risk of Malnutrition and Its Effects on the Quality of Life of Hospitalized Cancer Patients.
- C) Publications of chapters in national/international book
C1. Celik E. Preserving bone health in all stages of breast cancer. (Current Approaches to Breast Cancer) Ankara Nobel Tıp Kitabevleri, 2021. In English language.
C2. Celik E. Chemotherapy of cancer. (Basic pharmacology for health sciences) Ankara Nobel Tıp Kitabevleri, 2021. In Turkish language.
C3. Celik E. Primary thyroid lymphoma. (Book name: Multidisciplinary Current Approach to Thyroid Cancer), Logos yayincilik, 2019. In Turkish language.
D). Projects in which he worked as a sub-investigator in international scientific research projects (Phase II-III)
D1. Randomized, Open Label Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated Metastatic Non- Squamous Non-Small Cell Lung Cancer Patients With CEACAM5 Positive Tumors.
D2. A Randomized Double-blind, Placebo-controlled Study of Ribociclib in Combination With Fulvestrant for the Treatment of Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer Who Have Received no or Only One Line of Prior Endocrine Treatment.
D3. A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study of MEDI4736 as Sequential Therapy in Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy (PACIFIC).
D4. A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Various Regimens of Erdafitinib in Subjects With Metastatic or Locally Advanced Urothelial Cancer.
D5. A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Patients With EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
D6. A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC).
D7. A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab (Anti-Tigit Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer.
D8. A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation.
D9. A Phase II, Randomized, Double-Blind Placebo-Controlled Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer.
D10. A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet Chemotherapy.
D11. A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) as Monotherapy and in Combination With Platinum-Based Chemotherapy in Patients With Untreated Locally Advanced or Metastatic Urothelial Carcinoma.
D12. A Phase III, Multicenter, Randomized, Open-Label Study of Atezolizumab (Anti-PD-L1 Antibody) Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation.